登录 注册 会员服务 联系我们

HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

  • Published:2023-09-07 Issue:4 Volume:483 Page:497-507
  • ISSN:0945-6317
  • Container-title:Virchows Archiv
  • language:en
  • Short-container-title:Virchows Arch

Author:

Kendall Bártů MichaelaORCID,Němejcová Kristýna,Michálková Romana,Stružinská Ivana,Hájková Nikola,Hojný Jan,Krkavcová Eva,Laco Jan,Matěj Radoslav,Drozenová Jana,Méhes Gábor,Fabian Pavel,Hausnerová Jitka,Švajdler Marián,Škapa Petr,Cibula David,Zima Tomáš,Dundr Pavel

Funder

Ministerstvo Zdravotnictví Ceské Republiky

lékařská fakulta Univerzity Karlovy

European Regional Development Fund

BBMRI_CZ

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Reference55 articles.

1. Almstedt K, Heimes AS, Kappenberg F, Battista MJ, Lehr HA, Krajnak S, Lebrecht A, Gehrmann M, Stewen K, Brenner W, Weikel W, Rahnenfuhrer J, Hengstler JG, Hasenburg A, Schmidt M (2022) Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer 173:10–19. https://doi.org/10.1016/j.ejca.2022.06.012

2. Amano T, Chano T, Yoshino F, Kimura F, Murakami T (2019) Current position of the molecular therapeutic targets for ovarian clear cell carcinoma: a literature review. Healthcare (Basel) 7(3):94. https://doi.org/10.3390/healthcare7030094

3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X

4. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446–464. https://doi.org/10.1200/JCO.2016.69.4836

5. Bolton KL, Chen D, Corona de la Fuente RI, Fu Z, Murali R, Kobel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ, Moukarzel LA, Winham SJ, Armasu SM, Lester J, Elishaev E, Laslavic A, Kennedy CJ, Piskorz A, Sekowska M, Brand AH, Chiew YE, Pharoah P, Elias KM, Drapkin R, Churchman M, Gourley C, DeFazio A, Karlan B, Brenton JD, Weigelt B, Anglesio MS, Huntsman D, Gayther SA, Konner J, Modugno F, Lawrenson K, Goode EL, Papaemmanuil E (2022) Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-3817

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3